What Dexcom's latest 10-Q says: 10 signals
Dexcom filed its latest 10-Q with the SEC on Jul 30, 2026. It discusses acquisition completed, capacity constraint and capex increase.
Public (DXCM)Medical Equipment Manufacturing10,000+ employeesdexcom.comLinkedIn
- Filed
- Jul 30, 2026
- Filings
- 2
- Signals
- 21
10-Q · latest 10
What Dexcom's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 10 signals
Dexcom faces multiple class-action lawsuits over G7 device performance and reliability.
Following the launch of its G7 device, Dexcom is battling six overlapping class-action lawsuits alleging the product fails to perform as advertised, creating a significant legal and reputational crisis.
Dexcom spent $41.2M on an acquisition in Q2 2026, signaling integration needs.
$41.2M
Cash used for an acquisition
Board authorizes new $1.0 billion share repurchase program in May 2026.
The company initiated a new $1.0 billion share buyback program and repurchased over $600 million in stock in Q2 2026.
$1B
New share repurchase program authorization
Dexcom's international revenue grew 29% YoY, outpacing domestic growth.
International revenue grew to $400 million in Q2 2026, a 29% increase year-over-year, compared to 18% growth in the US.
$400M
International revenue for Q2 2026
29%
Year-over-year international revenue growth
Spent $41.2M on an acquisition in Q2 2026 to drive growth.
Dexcom increased its investing cash outflow by $41.2 million for an acquisition during the second quarter.
$41.2M
Cash used for an acquisition
Defending multiple securities class actions and derivative lawsuits.
The company is embroiled in several consolidated securities class actions and related stockholder derivative lawsuits alleging false and misleading statements regarding revenue forecasts and product functionality.
Dexcom plans significant investments in manufacturing facilities to support growth.
The company is proactively investing in its manufacturing operations and facilities to avoid future capacity constraints driven by commercial expansion.
- SEC EDGAR
10-Q
Filed · 11 signals
Dexcom faces six class-action lawsuits over alleged failures of its G6 and G7 CGM devices.
Multiple lawsuits from users allege that the company's core G6 and G7 products failed to perform as advertised regarding safety, accuracy, and reliability.
Facing six user class-action lawsuits over G6/G7 device reliability and performance.
Dexcom is defending numerous lawsuits from users alleging G6 and G7 devices fail to perform as advertised and were misbranded, creating intense pressure to invest in quality management systems (QMS), manufacturing process controls, and data analytics to mitigate legal risk.
A securities class-action alleges the company made false statements regarding the G7 device's accuracy, reliability, functionality, and manufacturing.
Showing 10 of 21 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Dexcom earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Raising full-year revenue guidance to over $4.6 billion.The company increased its 2025 revenue forecast, signaling strong business momentum and confidence in near-term growth. This indicates a healthy financial position and ability to fund new projects and investments. | |
| Developing 'Smart Basal' software, signaling major investment in app-based algorithms.The company has a new software module, 'DexCom Smart Basal,' under FDA and CE Mark review. This represents a significant R&D investment in software, AI/ML algorithms, and personalized digital health features, creating opportunities for technology partners. | |
| Facing gross margin pressure from higher-than-expected manufacturing scrap rates.The CFO disclosed that gross margin guidance was lowered due to high scrap rates from third-party component issues. This creates pressure to find cost efficiencies in manufacturing, quality control, and supply chain management. | |
| Intensely focused on OpEx leverage to offset margin shortfalls.To counteract gross margin pressures, management is focused on managing operating expenses and driving leverage. This indicates a strong interest in solutions that improve operational efficiency and reduce costs across the organization. | |
| Adding hundreds of thousands of new customers, driven by Type 2 market.The company continues to see massive customer acquisition, with a growing mix from the Type 2 diabetes population. This rapid scaling of the user base challenges their customer support, onboarding, and data management systems. | |
| Investing in randomized controlled trials to build a Type 2 evidence roadmap.DexCom is building a large-scale randomized controlled trial (RCT) to generate clinical evidence for CGM use in the Type 2 population. This investment in data collection and analysis is critical for their market access and advocacy strategy, requiring robust data management and analytics capabilities. |
Signal API · MCP
Track Dexcom with the Signal API
One POST /v1/companies/enrich call with dexcom.com returns Dexcom 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"dexcom.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about Dexcom 10-Q
When did Dexcom file its latest 10-Q?
What did Dexcom disclose in its latest 10-Q?
What did Dexcom say on its recent earnings calls?
Where can I read Dexcom's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .